Am I missing something?, page-16

Lots of dumping today. Are we getting some announcement Soon??

If the six week trial for XanaMIA started on 15 July, then the trial will complete at the end of this month.

Have they noticed some positive result already??? (since its nearly 3 weeks now apprx) so they are selling now to bring the price down and buy back later OR the study started showing no affect at all and they are selling now.

Sydney, 15 July 2021.

Actinogen Medical ASX: ACW (‘Actinogen’ or ‘the Company’) is pleased to announce
that the first patient has been enrolled in Part A of its two-part XanaMIA trial, which targets patients with Mild
Cognitive Impairment (MCI) due to Alzheimer’s Disease (AD). This follows Actinogen receiving ethics approval
from the Bellberry Human Research Ethics Committee to commence the XanaMIA Part A study, as announced
on 2 June 2021.
Part A is being conducted at 4 outpatient sites in Australia and will enroll 105 older healthy volunteers, aged
50-80 years old, in a dose-ranging study to confirm the minimum effective dose. The study will determine the
safety and efficacy of a 5mg and 10mg Xanamem dose on cognition (ability to remember and think), over 6
weeks. The trial will utilise an iPad testing method with the sensitive endpoints of the Cogstate Neurological
Test Battery, incorporating the Digit Symbol Substitution Test - a previously FDA-approved endpoint for
cognition.